Toxicity of sunitinib plus bevacizumab in renal cell carcinoma

J Clin Oncol. 2010 Jun 10;28(17):e284-5; author reply e286-7. doi: 10.1200/JCO.2009.27.1759. Epub 2010 May 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Kidney Neoplasms / drug therapy*
  • Male
  • Middle Aged
  • Pyrroles / administration & dosage
  • Pyrroles / adverse effects
  • Sunitinib

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Indoles
  • Pyrroles
  • Bevacizumab
  • Sunitinib